Global Gout Therapeutics Market to Reach $10.8 Billion by 2030
The global market for Gout Therapeutics estimated at US$3.2 Billion in the year 2022, is projected to reach a revised size of US$10.8 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2022-2030. NSAIDs, one of the segments analyzed in the report, is projected to record 16.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Urate-Lowering Agents segment is readjusted to a revised 18.7% CAGR for the next 8-year period.The U.S. Market is Estimated at $877.9 Million, While China is Forecast to Grow at 21.9% CAGR
The Gout Therapeutics market in the U.S. is estimated at US$877.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 21.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.7% and 13.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.Select Competitors (Total 42 Featured) -
- AstraZeneca plc
- GlaxoSmithKline plc
- Grunenthal Group
- Horizon Pharma Plc
- Ironwood Pharmaceuticals, Inc.
- JW Pharmaceutical
- Merck& Co., Inc.
- Novartis AG
- Regeneron Pharmaceuticals.
- Savient Pharmaceuticals
- Selecta Biosciences, Inc.
- Takeda Pharmaceutical Company Ltd.
- Teijin Pharma Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Gout Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Gout Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Urate-Lowering Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Urate-Lowering Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Colchicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Colchicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Chronic Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Chronic Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Acute Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Acute Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 22: World Gout Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
JAPAN
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Japan 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
CHINA
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 41: China Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: China 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
EUROPE
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Gout Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
FRANCE
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: France 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
GERMANY
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Germany 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Italy 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: UK 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Spain Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Spain 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Spain Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Spain 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Russia Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Russia 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Russia Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Russia 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Gout Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Gout Therapeutics by Type - NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Type - Percentage Breakdown of Value Sales for NSAIDs, Urate-Lowering Agents, Colchicine and Corticosteroids for the Years 2014, 2023 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Gout Therapeutics by Disease Condition - Chronic Gout and Acute Gout Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Gout Therapeutics by Disease Condition - Percentage Breakdown of Value Sales for Chronic Gout and Acute Gout for the Years 2014, 2023 & 2030
AUSTRALIA
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Gout Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca plc
- GlaxoSmithKline plc
- Grunenthal Group
- Horizon Pharma Plc
- Ironwood Pharmaceuticals, Inc.
- JW Pharmaceutical
- Merck& Co., Inc.
- Novartis AG
- Regeneron Pharmaceuticals.
- Savient Pharmaceuticals
- Selecta Biosciences, Inc.
- Takeda Pharmaceutical Company Ltd.
- Teijin Pharma Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 3.2 Billion |
Forecasted Market Value ( USD | $ 10.8 Billion |
Compound Annual Growth Rate | 16.4% |
Regions Covered | Global |